EPS Group’s EPS Healthcare Limited (Head Office: Hong Kong (Special Administrative Region), Director: Tsumoru Miyano, hereinafter referred to as “EPS HC”) has entered into a capital and business alliance with BioBeaute Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO: Yao Du, hereinafter referred to as “BioBeaute”) with the aim of expanding its business into Asia in the healthcare and cosmetics fields.

【Key Points of This Release】
・EPS HC and BioBeaute enter into a capital and business alliance to expand into Asia in the healthcare and cosmetics fields.
・EPS HC is involved in the trading of healthcare products for China and Southeast Asia, while BioBeaute is involved in the research and development of new technologies and products, contract manufacturing for Japanese and Chinese cosmetics companies, and support for their expansion into Asia.
・The functions of the two companies are complementary, and the capital and business alliance will accelerate the cosmetics business’ expansion into Asia.

【Details of This Release】
　EPS HC is a subsidiary of EPS Creative Health Technology Group Ltd. (Head Office: Hong Kong (Special Administrative Region), Executive Director and CEO: Kenichiro Washikita, hereinafter referred to as “EPS CHT”), a subsidiary of the EPS Group. EPS HC trades and sells health care products such as beauty products and health foods from Japanese manufacturers to China and Southeast Asia, and is also engaged in the development of original health care products as a new business.

　BioBeaute, in which EPS HC made the investment on February 20, 2025, supports Japanese and Chinese cosmetics companies in their expansion into Asia, and as business synergies are expected between the two companies, leading to the conclusion of a capital and business alliance.

　BioBeaute was founded by CEO Yao Du, who obtained her doctorate from the Graduate School of Pharmaceutical Sciences at the University of Tokyo and worked for a major global cosmetics company for many years. With her experience, she focused on the application of technological seeds born from basic research in academia to the beauty field, and established the company with the aim of “bridging academia and the cosmetics industry” and “bridging Japan and Asia”. Currently, the cosmetics market is growing rapidly in Asia, including China and Southeast Asian countries due to economic development. Cosmetics companies in each country are becoming essential to have functionality and technology that can differentiate them from others in order to survive in the market. With its background, BioBeaute provides the results of research into new functionality and formulation technologies to its main clients, Japanese and Chinese cosmetics companies, and also supports the expansion of sales of these products in Asia.

　EPS HC has noticed BioBeaute’s research and development capabilities and business model in the cosmetics field, and has decided that a business alliance will further grow the businesses of both companies. Through this business alliance, EPS HC will add the cosmetics sector to its business portfolio, and the collaboration between the two companies will promote business expansion in Asia.

【About EPS Healthcare Limited】
　As our core business, we have been introducing and supplying high-value products and services from overseas rapidly based on our accurate understanding of the needs of Japanese researchers involved in life science research, especially in the field of fundamental research. We also trade and wholesale Japan made health care products such as　food and beauty care products to China and Southeast Asia. In addition, we are involved in the development of our own health care products as a new business.

【About BioBeaute Co., Ltd.】
　BioBeaute was founded in 2024 with the aim of “bridging academia and the cosmetics industry” and “bridging Japan and Asia” by focusing on the application of technological seeds born from basic research in academia to the beauty field. We actively conduct applied research on new active ingredients and formulation technologies, and utilize our own market insight and product development capabilities to develop and sell new formulations both domestically and internationally.